ArticleInternational journal of nephrology and renovascular disease2011
Validity of urinary monoamine assay sales under the "spot baseline urinary neurotransmitter testing marketing model".
Article in International journal of nephrology and renovascular disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Parkinson's disease managing reversible neurodegeneration.Neuropsychiatric disease and treatment · 2016Article
- Management of L-dopa overdose in the competitive inhibition state.Drug, healthcare and patient safety · 2014Article
- Parkinson's disease: carbidopa, nausea, and dyskinesia.Clinical pharmacology : advances and applications · 2014Article
- Administration of supplemental L-tyrosine with phenelzine: a clinical literature review.Clinical pharmacology : advances and applications · 2014Review
- Self-reported sleep disturbance is associated with lower CD4 count and 24-h urinary dopamine levels in ethnic minority women living with HIV.Psychoneuroendocrinology · 2013Article
- 5-HTP efficacy and contraindications.Neuropsychiatric disease and treatment · 2012Article
- Relative nutritional deficiencies associated with centrally acting monoamines.International journal of general medicine · 2012Article
- The discrediting of the monoamine hypothesis.International journal of general medicine · 2012Article
- APRESS: apical regulatory super system, serotonin, and dopamine interaction.Neuropsychiatric disease and treatment · 2011Article
- Monoamine depletion by reuptake inhibitors.Drug, healthcare and patient safety · 2011Article
Corrections and comments
- Retraction · 2021-03-03Cites Retracted Work · Investigation by Journal/Publisher · Unreliable Data · Unreliable Results and/or Conclusions · Upgrade/Update of Prior Notice(s) ·
- Expression of concern · 2020-04-23Concerns/Issues about Data · Concerns/Issues about Results and/or Conclusions · Conflict of Interest · Investigation by Journal/Publisher · Updated to Retraction ·
- Expression of concern
- Retracted
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spot baseline urinary monoamine assays have been used in medicine for over 50 years as a screening test for monoamine-secreting tumors, such as pheochromocytoma and carcinoid syndrome. In these disease states, when the result of a spot baseline monoamine assay is above the specific value set by the laboratory, it is an indication to obtain a 24-hour urine sample to make a definitive diagnosis. There are no defined applications where spot baseline urinary monoamine assays can be used to diagnose disease or other states directly. No peer-reviewed published original research exists which demonstrates that these assays are valid in the treatment of individual patients in the clinical setting. Since 2001, urinary monoamine assay sales have been promoted for numerous applications under the "spot baseline urinary neurotransmitter testing marketing model". There is no published peer-reviewed original research that defines the scientific foundation upon which the claims for these assays are made. On the contrary, several articles have been published that discredit various aspects of the model. To fill the void, this manuscript is a comprehensive review of the scientific foundation and claims put forth by laboratories selling urinary monoamine assays under the spot baseline urinary neurotransmitter testing marketing model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.